Cytovac opts for Swedish brain cancer trial
Cytovac has halted a phase II trial with brain cancer patients in Denmark, in part because the testing was done too late in the disease cycle. The company is now launching a slightly different trial in Sweden instead.
BY LONNI LYNGE
The biotech company Cytovac never managed to wrap up a phase II study in Denmark with its candidate drug Alecsat targeting the rare, but deadly brain cancer type glioblastoma multiforme (GBM).
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
CytoVac reinforces board room
For abonnenter
CytoVac is talking to potential partners
For abonnenter
CytoVac wins special status in US as well
For abonnenter
